Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients
Categories
Biotechnology
Wockhardt Ltd Q3FY24; 0% rise in Revenue
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Laurus Labs Ltd Q3FY24; 89% fall in Profits
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients
Syngene International Ltd Q3FY24; 2% rise in Profits
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Laurus Labs Limited Q3 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY24 Earnings Concall Business Performance Gross margins remained resilient at over 52% for several
Laurus Labs Limited Q2 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY24 Earnings Concall Q2 FY24 Results Revenue declined 22% year-on-year to INR1,224 crores.. EBITDA
Syngene International Ltd Q2FY24; 14% rise in Profits
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Wockhardt Ltd Q1FY24; 8% rise in Revenue
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Shilpa Medicare Ltd Q1FY24; 50% fall in Profits
Shilpa Medicare is engaged in the business of high quality Active Pharmaceuticals Ingredients (APIs), Intermediates, Formulations, New Drug delivery system, Peptides, Biotech
Panacea Biotec Q4FY23 Earnings Story
Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited and was publicly listed in
Panacea Biotec Q4FY23; 8% Fall in Revenues
Panacea Biotec Ltd.’s revenue in Q4FY23 rose 13% to ₹ 12,557 crores. Consolidated Profit After Tax came at ₹ 4,320 crores in
Laurus Labs Limited Q4 FY23 Earnings Conference Call Insights
https://youtu.be/5Vtl-XMN8qg Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Management Update: [00:09:24]LAURUSLABS said it invested in expanding non-ARV formulation
Laurus Labs Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Management Update: [00:03:57] LAURUSLABS said its strong results were driven by
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Syngene reported a 5% rise in its net profit for Q3FY23
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated January 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Shares of Biocon research arm soars as it reports 23% rise in its revenue
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Transcript
Biocon Limited (NSE: BIOCON) Q2 FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Saurabh Paliwal -- Head, Investor Relations Kiran Mazumdar
Dishman Carbogen Amcis Ltd (DCAL) Q2 FY22 Earnings Concall Transcript
Dishman Carbogen Amcis Ltd (NSE: DCAL) Q2 FY22 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Arpit Vyas -- Global Managing Director Pascal Villemagne -- Vice
Laurus Labs Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/ZaM0EH45MvA Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Management Update: [00:10:45] LAURUSLABS said that on the R&D front,
Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Transcript
Laurus Labs Limited (NSE:LAURUSLABS) Q2 FY23 Earnings Concall dated Oct. 21, 2022 Corporate Participants: Satyanarayana Chava -- Chief Executive Officer V.V. Ravi Kumar -- Chief Financial Officer Analysts: